GLP-1 Plan Exclusion vs Prior Authorization: How to Tell What Your Denial Means

By The RX Index Editorial Team · Last verified August 24, 2026

Disclosure: This page is free to use. Some links further down are affiliate links, which means The RX Index may earn a commission at no extra cost to you. Affiliate relationships do not change how we classify a denial or which next step we recommend.

This guide is general education. It is not medical, legal, or plan-specific benefit advice. Your denial letter, your plan documents, your insurer, and your clinician control your actual situation.

---

Here is the short answer on GLP-1 plan exclusion vs prior authorization. A prior authorization means your plan may pay, but wants proof first. A plan exclusion means the drug, benefit, or use may sit outside your plan, so a normal prior authorization cannot add it. One is usually a proof problem. The other is a plan-terms problem. Your written denial tells you which — if you know the words to look for.

That difference is not a technicality. It decides whether your doctor's records can fix the problem, whether an outside reviewer may be able to look at it, and whether you should spend the next three weeks fighting or spend the next twenty minutes finding a different door.

Here is the part almost nobody tells you: "excluded" and "nothing else is covered" are not the same sentence. In the nine Massachusetts decisions we checked, flat-looking denials sometimes turned on a separate covered indication, a preferred drug, or a rule that later changed. Cigna's current public policy libraries also list named GLP-1 Benefit Exclusion Overrides beside ordinary prior authorization policies. None of that means you qualify. It means you should read the actual rule before you quit.

We will show you those decisions and the named policies below. First, let's figure out which denial you are holding.

---

This page is for you if:

• Your denial mentions prior authorization and exclusion, and you cannot tell which one is real
• Your doctor says you qualify, but the plan says it will not pay
• You found the drug on a formulary, and your plan still said no
• You do not know whether to call the doctor, the insurer, the pharmacy, or HR
• You are trying to decide if one more appeal is worth your time

This page is not for:

• Deciding whether a GLP-1 is right for you medically — that is a conversation with a clinician
• Finding a way to use a diagnosis you do not have (we will not help with that, and it can hurt you)
• Comparing telehealth providers before you know what your insurance barrier actually is → start with how to get insurance to cover a GLP-1

---

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

---

The 10-second version

PBM means pharmacy benefit manager — the company your health plan hires to run the drug side of your benefits. It is often a different company than the one on your insurance card, and it may be the company that returned the pharmacy rejection.

### Decode the words on your denial Pick the exact phrase you were given. The matrix below shows the likely denial type, the right first call, and the document to request. → Match My Denial Words to the Next Step Free. No form or email. Do not post your name, member ID, or medical details.

---

What we actually verified for this guide

We checked these ourselves on August 24, 2026, at the agency, law, payer, insurer, or provider that issued the rule or claim:

• Federal internal appeal and external review rules in 45 CFR 147.136, including which plans and denial types those rules cover
• The narrower federal protection for ending a previously approved course of treatment before its approved end
• Current internal and external review deadlines, including the live October 2, 2026 filing extension for certain HHS-administered cases
• The Medicare Part D weight-loss exclusion in the Social Security Act and the separate appeal rule for plan-applied exclusions
• The current Medicare GLP-1 Bridge dates, $50 monthly copay, covered products, prior authorization flow, and resubmission rule
• Pharmacy rejection code meanings in current official payer and state code tables
• Nine official Massachusetts GLP-1 hearing records and the published decision text available through Mass.gov
• ERISA's written plan-document request rule and its court-enforced penalty provision
• Cigna's current public policy indexes, which list ordinary GLP-1 prior authorization policies and separately named GLP-1 Benefit Exclusion Override policies
• Ro's current coverage-checker scope, insurance-concierge description, product list, and membership pricing
• Current FDA-approved uses named on this page, plus FDA's status rule for compounded drugs

What we could not verify for you personally: whether your plan excludes this, what your letter says, whether your appeal will win, or what you will pay. Nobody can promise you those. Anyone who does is selling something.

---

GLP-1 plan exclusion vs prior authorization: What is the difference?

Prior authorization means the plan may cover the medication, but only after it receives proof that its rules are met. A plan exclusion means the plan says the drug, drug class, benefit, or use sits outside what it covers. A standard prior authorization request usually cannot add a benefit the plan excluded, though some plans publish a separate override process.

Think of it as two different questions asked by two different people.

Prior authorization asks: did you prove it?

The benefit may be sitting there. Your plan wants to see something before it pays — a diagnosis, a measurement, a record of what you tried first, or the correct form. Your prescriber sends it in. The plan reviews it. This is a proof problem, and a proof problem can often be fixed when the plan names a real gap.

A plan exclusion asks: is it even in there?

Somebody decided, before you ever filled the prescription, that this plan would not include that drug, benefit, or use. On a job-based plan, the employer or plan sponsor may control that design. On another kind of plan, the issuer, state program, or federal law may control it. Sending better records into a true exclusion is like sending a better resume to a company that is not hiring. The paperwork was never the issue.

The 30-second test

Read your denial and ask one question:

Is the plan saying "we may cover this after you prove X"? That is usually a prior authorization or rules problem. Is the plan saying "this benefit is not part of your plan"? That is usually an exclusion problem.

Now the honest qualifier, because this is where cheap advice gets people stuck: "excluded" should not make you quit. It should make you ask one specific question, which we give you word for word below.

Cigna gives us a current, public example. Its general drug-policy index lists BEO005 and BEO006, both called Weight Loss – Glucagon-Like Peptide-1 Agonists Benefit Exclusion Overrides. Its National Formulary index separately lists CNF915, CNF908, and CNF950 as GLP-1 Benefit Exclusion Override policies — beside an ordinary GLP-1 prior authorization policy, CNF684. Those names prove that an override path exists in Cigna's policy library. They do not prove that your Cigna plan includes one or that you meet its rules.

That is the whole reason to ask by name instead of assuming.

---

How do I tell which kind of GLP-1 denial I have?

Start with the final reason in the written denial, not a pharmacy counter message or a symbol next to a drug name. "Prior authorization required," "criteria not met," "non-formulary," and "not a covered benefit" point to four different problems with four different fixes. If the wording conflicts, ask the plan to name the member-specific reason and the plan provision behind it.

Four checks, in this order.

1. The written denial beats everything else on the reason for this claim

There is a ranking of evidence here, and most people work it backwards.

1. Your formal written denial — the strongest evidence of why this claim was denied
2. Your member-specific plan document — the document that controls the benefit
3. Your member-specific formulary
4. The insurer or PBM portal
5. The pharmacy's rejection message
6. A general public drug list
7. What someone said in a forum

For plans subject to the federal claims-and-appeals rules, the denial notice has to explain the reason, identify the rule used, and tell you how to dispute the decision. Other plan types have their own notice rules. If you do not have a written decision, that is your first phone call, before anything else.

2. The pharmacy code — the fastest clue most people never ask for

When your pharmacy runs your claim, it gets a rejection code and message. That code is a clue, not a final reading of your plan contract. It can still tell you which lane to investigate while you wait for the written denial.

Source check: official Louisiana Medicaid, New York Medicaid/NYRx, and MaineCare pharmacy code materials. Verified August 24, 2026.

The line that matters most here: code 70 and code MR both feel like "no." They are not the same clue. MR points to this exact product's formulary status. Code 70 points to a broader noncoverage edit. Neither code, by itself, replaces the formal written reason.

Call your pharmacy and ask: "What exact rejection code and full message came back on my claim?" Ask them to read both.

3. Run it through the Four-Gate Test

Every GLP-1 claim has to clear four gates. Your denial or rejection stopped at one of them. Once you know which, you know who to call.

The Four-Gate Test is The RX Index's framework. It separates benefit design, formulary status, utilization rules, and claim processing so one kind of "no" is not mistaken for another.

4. Match your exact words to your exact next move

What if my letter says both?

This trap is common, and it is not your fault.

A drug can carry a general prior authorization rule and sit under a member plan that excludes the benefit. A portal may show the general drug rule, not your plan's final answer. So you see "PA required," feel a flicker of hope, and spend two weeks on paperwork that could never have worked.

Real reader language: One person posting about a denial said the notice showed both "Prior Authorization Needed" and "Benefits exclusion." (r/Zepbound) Another put it more bluntly: "I feel like I'm losing my mind trying to figure out prior authorization." (r/Zepbound) These quotes show the confusion. They are not evidence about how a plan works or how an appeal will turn out.

If your notice has both, say this on the phone:

"My notice shows both a prior authorization requirement and a benefit exclusion. Which one is the actual basis for this member-specific denial, and what plan provision controls it?"

You are not being difficult. You are asking for the actual stated basis before you spend more time.

### Not sure who owns the next step? Use the call matrix below. It tells you who controls each denial lane and gives you the exact first question. → Show Me Who to Call First

---

Can prior authorization override a GLP-1 plan exclusion?

Usually not. A prior authorization proves you meet the rules for a benefit your plan may cover. It does not add a benefit the plan left out. Some plans publish a separate benefit-exclusion override process, so the right move is to ask whether yours has one by name — not to assume the answer is final either way.

The honest part, first

Another ordinary prior authorization is probably a waste of your time if the real reason is a true benefit exclusion. More BMI records will not change it. A stronger letter from your doctor will not change it. Switching telehealth companies will absolutely not change it, no matter what their ad says. We would rather tell you that in minute one than let you find out in week four.

Here is why that is actually good news. It means you can stop doing the thing that was never going to work and start doing three things that might. And the first one takes a single phone call.

Ask this exact question

Copy it. Read it out loud if you have to.

"Is this denial based on failing to meet prior authorization criteria, or is this medication or use excluded under my member-specific plan? If it is excluded, does my plan have a benefit-exclusion override, an exception process, or a separate policy for another diagnosed condition?"

That last clause is the one people skip. Cigna's current public indexes prove why it belongs there: they list named GLP-1 Benefit Exclusion Override policies separately from ordinary GLP-1 prior authorization policies. Two different policy types. Two different questions. The policy name still does not prove your member plan includes it, so ask the plan to check your coverage — not just the public library.

Why an outside reviewer usually cannot rewrite a clean exclusion

This is the mechanism almost no page explains, and once you see it, everything makes sense.

When the federal external review rules apply, certain denials can go to an independent review organization — an outside reviewer, not your insurer. But that lane is limited. It is mainly for denials that involve medical judgment, such as medical necessity, appropriateness, care setting, level of care, experimental treatment, or the effectiveness of a covered benefit.

A clean contract exclusion may use no medical judgment at all. Somebody made a benefit-design decision.

The federal rule also tells the outside reviewer to consider the terms of the claimant's plan or coverage and make sure the decision is not contrary to those terms.

Read that again. The outside reviewer can review medical judgment. It cannot add a benefit that the governing plan terms leave out.

But here is the crack in the wall

The same federal rule includes a worked example that matters here.

A plan excludes out-of-network care — unless the service cannot effectively be provided in network. The member is denied because the provider is out of network. That looks like a flat exclusion. But applying the written exception requires a clinical judgment about whether in-network care can work.

In the example, the denial is eligible for external review because the exception requires medical judgment. The rule also says the notice failed to adequately communicate the reason because it did not explain why that exception did not apply.

Now apply the lesson carefully. If your exclusion contains a clinical exception, your dispute may involve medical judgment instead of pure plan design. Ask whether the decision applied that exception, whether the notice explained it, and whether external review is available under your plan's process. The existence of any carve-out does not automatically make every denial externally reviewable.

This is why "get the exclusion in writing" is not busywork. You are looking for the exact boundary, any allowed exception, and the reason the plan says you fall outside it.

What not to do

• Do not send the same prior authorization again without knowing the exact stated gap
• Do not pay anyone who promises "guaranteed approval." Nobody can promise that
• Do not assume a new doctor fixes a plan benefit
• Do not treat a general public drug list as proof of your own coverage
• Do not use a diagnosis you do not have. Ever. It is fraud, and it puts the clinician at risk too

---

What nine real denial decisions show about which arguments actually work

Massachusetts publishes full GLP-1 hearing decisions with the rule, the record, the member's argument, and the hearing officer's result. We checked nine official decisions. The useful pattern is narrower than "appeals work" or "appeals never work": clear benefit rules were enforced as written, while criteria disputes turned on the exact record and the version of the rule in force.

Almost nobody in the GLP-1 world reads these. They are public, they are free, and they show how a neutral decision-maker separates "you did not prove it" from "this use was not available under the rule."

Read this before the table. These are Massachusetts Medicaid hearing records, not employer plans. They do not tell you how often commercial appeals win, and your plan's process is different. They show the logic used in these nine decisions — nothing more.

Sources: official Massachusetts Board of Hearings decision records on Mass.gov. Checked August 24, 2026.

What these records did not reward

If your appeal rests only on one of these, rewrite it before you send it:

• "This drug works better than the preferred one." The reviewer still has to apply the written rule.
• "Covering it now will save money later." That does not replace a stated coverage criterion.
• "I was already taking it, so I should be grandfathered." The member in case 2506857 made a grandfathering argument; the written preferred-drug rule still controlled.
• "It is FDA-approved." FDA approval allows marketing for an approved use. It does not force a health plan to include the drug or use.

What actually matters

• A documented medical reason the preferred drug cannot be used, when the written rule allows that exception
• Current records that meet a named criterion
• Proof that the plan used the wrong rule, drug, form, indication, or effective date
• A policy version that changed before the dispute was finished

The finding that should change how you think about dates

Look again at case 2410692. The member lost under a rule requiring a semaglutide trial. Then the hearing officer added a footnote: by the date the decision was written, the drug list had been revised, and that requirement was gone.

The rule that beat the member had changed while the case was pending.

Criteria are time-stamped. They can change at plan renewal and sometimes during the year. Before you accept a "criteria not met" denial as permanent, ask one question: "What is the effective date of the policy you used, and is it still the current version?"

Contracts are stubborn. Criteria can move.

---

Is "non-formulary" the same as a plan exclusion?

No. Non-formulary usually means the exact drug is not on your plan's covered or preferred list, so a covered alternative or a formulary exception may be available. A benefit exclusion is broader — the plan may leave out the whole drug class, benefit, or use. Treating the two as the same thing can waste weeks and money.

A formulary is your plan's list of covered drugs, plus the rules attached to each one. A formulary exception is a request to cover a drug that is not on that list, or to waive a formulary rule. Medicare defines that process for Part D. Commercial plans use their own written terms and names.

Ask this before you appeal anything:

"If this exact medication is non-formulary, which medication is preferred for the same covered use, and what does my prescriber need to submit to request an exception?"

Sometimes the answer is a drug you would have been fine with, covered at a copay, available this week. That is not settling. That is winning the fast way.

---

Why does my plan cover a GLP-1 for diabetes but not for weight loss?

Because coverage rules often attach to a product and a reason for use, not just to the active ingredient. The same product can have more than one FDA-approved use, and two products with a related ingredient can sit under different plan rules. Coverage for one use does not prove coverage for another.

Case 2514230 is the cleanest example in this set. The rule denied Wegovy and Zepbound when used for adult overweight or obesity, then said they "may still be payable for other medically accepted indications." The decision applied separate cardiovascular criteria.

The exclusion and the separate-use path were printed in the same rule.

The member did not meet that path, so the denial stood. But the lesson is still useful: the exact use matters, and it must be real, diagnosed, and supported by the product's current policy.

Separate FDA-approved uses that exist right now

If weight-loss coverage is closed on your plan, these are different FDA-approved uses your clinician may recognize — only if you actually have the condition. An FDA-approved use still does not force your plan to cover it.

FDA labels and approval pages checked August 24, 2026. Product form matters. Coverage still depends on your member plan.

The hard line, said plainly

You never change a diagnosis to fit a rule, and neither does your doctor. Not "technically." Not "just to see." The honest question is whether a condition you actually have was submitted under the correct product and policy.

Ask your clinician: "Do I have another diagnosed condition with its own FDA-approved use and coverage policy for this product?" Then let them answer. That is the whole move.

---

What should I do if this is a prior authorization problem?

Get the plan's exact written criteria for your exact drug, form, and reason — then compare them line by line against what your prescriber actually sent. A corrected submission or an appeal can work when the plan named a specific gap. Sending the same packet again usually does not.

Good news first: you may be on the more fixable side. But confirm the benefit before you assume code 75 means coverage exists.

Step 1 — Ask for the actual criteria

Not a summary. The policy. Ask for:

• The policy title and number
• Its current effective date
• The initial-treatment criteria
• The renewal or continuation criteria
• The required diagnosis or indication
• Which records they need
• Any step therapy or quantity rules
• Whether the correct next move is a corrected submission or a formal appeal

Step 2 — Two rights that cost you nothing

For plans subject to the federal ACA claims-and-appeals rules, these rights are written into 45 CFR 147.136:

• The denial notice must include a denial code and its meaning, plus a description of the standard the plan used.
• You can ask for the diagnosis code and treatment code and what they mean — and that request is not itself an appeal.

Not every plan type is governed by that exact regulation. Your denial notice should tell you which process applies. Either way, asking the plan to identify the code, criterion, and governing policy does not weaken your case.

Step 3 — Fill in this grid with your prescriber's office

Step 4 — Correct, or appeal?

Correct and resubmit when: the wrong form was used, a document was left out, the wrong drug or use was processed, or the plan explicitly asked for more information. This is usually the fastest path.

Appeal when: your records appear to meet the policy, the plan applied the wrong rule, the plan ignored what you sent, or the disagreement is genuinely about medical judgment.

Step 5 — Keep a coverage log

One page. Date, who you spoke to, department, reference number, exactly what they said, what they promised, and the follow-up date. Keep the denial, policy, submission, fax or portal receipt, and every appeal copy. A clean record stops the next person from turning the call into a memory contest.

---

### If your denial was prior authorization, this is where a coverage team can earn its fee Missing, mismatched, or untracked information can sink a request. The value of a paid service is the benefit check, the correct submission, and the follow-up — not a promise that your plan will say yes. Ro offers a free GLP-1 insurance coverage report and, for Ro Body members, an insurance concierge that Ro says checks benefits and submits prior authorization paperwork. Its free checker currently reports on the Ozempic pen, Wegovy pen, and Zepbound pen. Ro also offers FDA-approved cash-pay products, including Zepbound and Foundayo, when prescribed.

Sponsored affiliate link. Opens in a new tab.

Ro claims: provider-stated vs independently checked

Who should skip this and why. Ro is not free once you join — there is a membership fee on top of medication, and no company can promise your plan will approve anything. If your denial was a true benefit exclusion, a telehealth membership does not change your plan's contract, so skip to the next section. If you are using Medicare or Medicaid, start with the official program and plan routes on this page. If your current prescriber's office handles prior authorizations quickly and well, you may not need to pay anyone for this at all.

That is the honest version. A coverage team is worth money when the value is the coverage work — the benefit check, paperwork, and follow-up — not when you already have that covered.

---

What should I do if this is a true GLP-1 plan exclusion?

Get the exact exclusion in writing and find out whether it covers one drug, all anti-obesity drugs, or only one use. Then ask about a named override, the plan-design owner, and the next plan year. If none of those paths exists, stop treating it like missing paperwork and compare other treatment paths.

Step 1 — Get it in writing, with the specifics

Ask for all of it:

• The exact plan-document language
• The section and page number
• The effective date
• Whether the exclusion covers one drug, all anti-obesity medication, one form, all weight-management use, or all uses
• Whether the denial came from the insurer, PBM, plan administrator, or employer plan
• Whether a benefit-exclusion override or exception exists
• Whether another real diagnosed condition has its own policy
• Whether the exclusion changed during your current plan year

Step 2 — The letter that makes them show you the rule

If your coverage comes through a private employer and the plan is governed by ERISA, you have a lever most people never use.

Send a written request to the plan administrator for the Summary Plan Description and the other plan documents listed in ERISA §104(b)(4), including the instruments under which the plan is established or operated. The administrator generally has 30 days after the request. If the administrator does not comply, a court may impose a penalty of up to $110 per day.

Three honest limits, because this gets oversold online:

1. The penalty is a judge's decision, not an automatic check.
2. The rule is for ERISA plans. It does not govern Medicare, Medicaid, individual-market coverage, government plans, or most church plans.
3. The request right covers the documents named by the law. It does not turn every internal email, vendor manual, or business record into a required plan document.

What it is good for: forcing a phone-only answer into a document you can read. You cannot test the exclusion, effective date, or exception clause until you can see the language.

Send the request in writing. Address it to the plan administrator named in your Summary Plan Description or benefits materials. Keep a copy and proof of delivery.

Step 3 — Ask whether your job plan is self-funded or fully insured

This changes who owns plan design and which regulator may help.

• Fully insured means the employer buys an insurance contract. The employer chooses among benefit options, the insurer issues and administers the contract, and state insurance law generally applies to the policy.
• Self-funded means the employer or plan sponsor pays claims and often hires an insurer or PBM to administer them. State insurance-benefit mandates generally do not apply to an ERISA self-funded plan in the same way, though federal law still does.

The practical translation: on a self-funded plan, the employer or plan sponsor usually controls the benefit design. The insurer or PBM may still be the right place to correct a bad claim or a misapplied rule, but it usually cannot add a benefit the sponsor did not include.

Script for HR or your benefits administrator:

"Does our plan exclude anti-obesity medications as a benefit, or is this only a formulary decision on one drug? Is our plan self-funded or fully insured? Who controls this plan term, and is there a member exception or a review for the next plan year?"

Be realistic: HR usually cannot fix an individual clinical decision. What the benefits team can do is identify the plan type, tell you who owns the design, confirm whether an exception exists, and record demand before renewal. All four are worth the email.

---

Can I appeal a GLP-1 plan exclusion?

You can often file an internal appeal, but its job should be to test whether the exclusion was applied correctly or whether an allowed exception exists — not to argue that a doctor's letter should rewrite the benefit. External review is strongest for medical-judgment disputes, so a clean contract exclusion often falls outside that lane.

HealthCare.gov lists "the benefit isn't offered under your health plan" among decisions that can go through an internal appeal for plans covered by that process. So the door is not locked. It just leads somewhere specific.

An appeal has a real job when:

• The plan cited the wrong exclusion
• The exclusion does not apply to your requested drug, form, or use
• The plan ignored an override it publishes
• The plan applied a general policy instead of your member-specific benefit
• The wrong drug or form was processed
• The decision is really about medical necessity or a clinical exception
• Your denial letter names an exception route
• The policy version or effective date was wrong

An appeal is lower-yield when:

• Your plan document clearly excludes the benefit
• The plan has confirmed in writing that no override exists
• The appeal repeats the same records without answering the stated reason
• The argument is only that the drug is helpful, popular, or FDA-approved

Lower-yield, not impossible. Your plan's own terms and process control.

Internal appeal vs external review

Two procedural rights from the federal rules are worth knowing, but neither is automatic in every case:

• A serious failure to follow the claims-and-appeals rules can let you treat internal review as exhausted. The rule has an exception for some de minimis, nonprejudicial violations, so record the exact failure and get plan-specific help before skipping a step.
• In the federal external review process, the plan normally has five business days to send the outside reviewer the documents it considered. If it misses that deadline, the reviewer may terminate the review and reverse the denial. The plan may then ask the reviewer to reconsider if the documents are supplied.

Deadlines cut both ways.

→ Read the official HealthCare.gov external review guide before filing.

---

Who should I call first — the insurer, PBM, doctor, pharmacy, or HR?

Call whoever controls the gate that failed. Your prescriber handles clinical records. The insurer or PBM explains the drug rule. The pharmacy identifies claim-processing problems. The plan administrator or benefits team may control plan-design questions on job-based coverage.

Pharmacy script: "What exact rejection code and full message came back? Does it point to authorization, formulary status, product or form, refill timing, network, diagnosis, age, or another edit?"

Prescriber script: "The denial says [exact phrase]. Please compare what was submitted against policy [number and date]. What specific item was missing, and should we correct the request or file an appeal?"

---

Does my type of health plan change what I can do?

Yes. Job-based plans, Marketplace plans, Medicare, and Medicaid do not all use the same appeal path or the same regulator. Identify your plan type first, then follow the instructions in your own denial notice.

How to tell in 30 seconds: ask HR one question — "Is our medical plan self-funded or fully insured?" That is a normal benefits question. The Summary Plan Description may also say.

---

What if I'm on Medicare?

Medicare has two different kinds of "no," and they do not lead to the same place. A category excluded by federal law cannot be added to standard Part D by a normal exception. A coverage rule your Part D plan applies can be challenged through the Part D coverage-determination and appeal process. Weight-management GLP-1s also have a separate CMS Bridge path through December 31, 2027.

This distinction is precise, it is in the law, and mixing it up costs people months.

The statutory category

Federal law ties the Part D definition of a covered drug to a list that includes "agents when used for anorexia, weight loss, or weight gain" among excludable categories.

Note the wording: when used for. The rule attaches to the use, not every use of the product or molecule. That is why a GLP-1 may be handled differently when prescribed for a separate Part D-coverable indication.

An appeal cannot erase the statutory weight-loss category. It can still test whether the plan classified your use correctly, applied the right product policy, or ignored a Part D-coverable indication.

A Part D plan decision

The same Social Security Act section says exclusions a Part D plan applies under its own authority are determinations subject to reconsideration and appeal.

So do not stop at the word "excluded." Ask:

"Is this denial based on the federal weight-loss category, or is it a plan coverage determination for a Part D-coverable use?"

The Medicare GLP-1 Bridge

CMS launched a separate program on July 1, 2026, and has extended it through December 31, 2027. For eligible Part D members using an included drug for weight management, the copay is $50 per monthly supply.

As of August 24, 2026, CMS lists:

• Foundayo
• Wegovy injection and tablets
• Zepbound KwikPen

Four details matter:

1. The Bridge uses prior authorization. CMS's form requires a denied pharmacy claim through the Bridge routing before the PA request is completed.
2. A Bridge PA denial has no appeal inside the Bridge process. The prescriber can resubmit corrected or additional information. Separate Part D appeal rights still apply to a Part D coverage determination.
3. The Bridge is for weight-management use. A product prescribed for a Part D-coverable use — such as Zepbound for qualifying obstructive sleep apnea or Wegovy for a qualifying cardiovascular indication — should be handled through the Part D plan, not shifted to the Bridge.
4. The $50 Bridge copay does not count toward Part D true out-of-pocket costs (TrOOP) because Bridge coverage sits outside the Part D benefit payment flow.

→ Read the Medicare GLP-1 Bridge guide for the current eligibility questions, covered products, pharmacy flow, and cost.

---

What if I was already taking it and got cut off?

Do not assume that being mid-treatment automatically keeps coverage alive. The federal concurrent-care rule is narrower: when a plan has already approved an ongoing course of treatment for a set period or number of treatments, it generally cannot reduce or end that approval early — other than through a plan amendment or termination — without advance notice and time for review.

That rule can matter. But it does not automatically extend an expired prior authorization, block a lawful formulary or benefit change, or guarantee another refill after the approved period ends.

A refill that suddenly fails after months usually means one of five things:

1. Your authorization expired and needs renewal
2. The formulary or benefit changed
3. The plan switched to a different preferred product
4. New continuation criteria applied
5. A previously approved course was cut short before its approved end

Those are different problems. Do not let anyone answer all five with "not covered."

Your first 24 hours

1. Ask the pharmacy for the exact rejection code and full message
2. Call the plan and ask which of the five happened
3. Ask whether a transition fill, temporary supply, or override is available under your plan
4. If the plan cut a still-active approval short, ask: "What was the approved end date, and when was advance notice sent?"
5. Send the denial and dates to your prescriber before changing or stopping treatment

One warning from the hearing records: renewal criteria can depend on the starting numbers. If you are approved today, keep your baseline measurement, start date, dose history, response, side effects, and renewal deadline. Future you may need them.

---

How long do I have to act?

For many group and individual plans subject to the federal ACA appeal rules, you generally have 180 days from the denial notice to file an internal appeal and 4 months from the final internal denial to request external review. Medicare, Medicaid, and some other plans use different timelines. Your own notice controls — and a live federal extension may have reopened a window you thought was closed.

### Your external-review window may have reopened — check this today CMS currently says you may have until October 2, 2026 to request external review if:

• Your original deadline fell between July 1 and August 3, 2026, and
• Your plan uses the HHS-administered Federal External Review Process

The notice names Alabama, Florida, Georgia, Texas, Wisconsin, U.S. territories other than Puerto Rico, and state or local government plans in any state. Call your plan and ask: "Does my plan use the HHS-administered Federal External Review Process, and does the October 2, 2026 extension apply to my denial?" Verified August 24, 2026. This is time-limited. Confirm it before relying on it.

You can appoint an authorized representative, including a doctor, to request an external review for you when the applicable process allows it.

---

When should I stop appealing and choose a different treatment path?

Stop repeating the same appeal when the plan has confirmed a clear exclusion in writing, no override applies, and another review would only restate the same facts. Keep going when the wrong rule was used, records were missing, the wrong drug or use was processed, or an available exception has not been tried. This is a math question, not a willpower question.

Permission, in plain words

Finding a true exclusion does not mean you failed. It does not mean you did not try hard enough, and it does not mean you did not deserve treatment. It means the obstacle was the plan's design — a decision made before you ever filled the prescription.

That is not a verdict on you. It is a fact about a contract.

Once you have that in writing, it is completely reasonable to stop mailing paperwork into a wall and start comparing paths that do not depend on that excluded benefit. That is not giving up. That is aiming at the target that is actually there.

Keep your options clearly separated

When you compare paths, keep these four categories distinct — because they are not the same thing and should never be presented as if they were:

1. Insurance-covered FDA-approved medication — if another covered product or real covered use applies
2. FDA-approved cash-pay medication — a prescription product paid for outside your insurance benefit
3. Other clinician-guided treatment options — including non-GLP-1 medicines or non-drug care your plan may cover
4. Compounded medication — not FDA-approved. FDA does not review a compounded drug for safety, effectiveness, or quality before it is marketed. It should not be described as a generic, copy, or equivalent of an approved product

A compounded drug may be considered when a licensed prescriber determines that a patient's needs cannot be met by an available FDA-approved drug and applicable compounding rules are met. That is a clinical and legal boundary, not a cheaper-brand shortcut.

Your clinician decides what is medically appropriate. Our job is to make sure you know which category you are looking at.

### Find the treatment path that fits your situation Answer a few questions about your state, insurance situation, medication preference, and budget. You will get a personalized shortlist with source-verified pricing — with FDA-approved and compounded paths kept clearly separate. → Get My Personalized GLP-1 Treatment Path Free. About 60 seconds. No signup.

---

How we built this guide

We classified denial language using current federal rules, official program materials, insurer policy indexes, pharmacy code tables, FDA sources, and published hearing records. Then we separated source-backed facts from our own next-step framework. Time-sensitive items carry a verification date. Where only a member-specific plan document can answer the question, we say so instead of guessing.

Our source order

1. Your member-specific denial and governing plan document
2. Current insurer, PBM, plan, or program criteria that apply to your exact coverage
3. The agency or legislature that issued the rule — CMS, the Department of Labor, HealthCare.gov, FDA, the Social Security Act, and state agencies
4. Official hearing decisions and payer code tables
5. The RX Index's Four-Gate Test and decision framework, labeled as ours
6. Forums, used only for how people describe the confusion — never as evidence about coverage rules or outcomes

What we verified

• The scope of the federal internal appeal and external review rule, including its medical-judgment boundary and worked exception example
• The narrower federal concurrent-care protection for a previously approved course of treatment
• Internal and external review filing windows and the live October 2, 2026 extension
• The Medicare Part D statutory category and the separate appeal rule for plan decisions
• Current Medicare GLP-1 Bridge dates, products, $50 copay, PA flow, and no-Bridge-appeal/resubmission rule
• Pharmacy rejection code meanings in official payer and state tables
• Nine official Massachusetts GLP-1 hearing records and published decision text
• ERISA's plan-document request rule and the up-to-$110-per-day court penalty
• Current Cigna policy-index entries for ordinary GLP-1 PA and separately named Benefit Exclusion Override policies
• Current FDA-approved uses and FDA's compounded-drug status statement
• Ro's provider-stated checker scope, concierge description, product availability, and membership price

What we did not verify for you

Your coverage. Your medical eligibility. Whether your employer will change the benefit. Whether your appeal will succeed. What you will pay. Those answers live in documents and facts only you, your plan, and your clinician can supply.

Update log

---

Frequently asked questions

Does prior authorization mean my GLP-1 is covered?

No. It means the claim hit a rule that requires review. The benefit may exist, but the PA message alone does not prove that it does. Approval, final coverage, and your cost stay open until the plan decides and the claim processes.

Does pharmacy code 70 prove I have a plan exclusion?

No. Code 70 is a broad Product/Service Not Covered message. Some payer tables use it for a plan or benefit exclusion, but the code alone is not your plan contract. Ask for the full message and the formal written reason.

Can my doctor's medical-necessity letter beat a plan exclusion?

Usually not on its own. A letter helps when the exclusion was applied to the wrong situation, the plan has an override, or the dispute is really about a clinical exception. It does not add a benefit the plan left out.

What does "not a covered benefit" mean?

It usually means the plan says the requested drug, benefit, or use is not part of your coverage. Ask for the exact plan provision, section, page, effective date, and any override or exception. Get it in writing.

Is "not medically necessary" the same as excluded?

No. "Not medically necessary" points to criteria or medical judgment. "Excluded" points to plan design. A medical-judgment denial may fit external review when the applicable process covers it; a pure benefit-design dispute often does not.

Is non-formulary the same as not covered?

Not always. Non-formulary usually means this exact drug is not on the covered list. A preferred alternative or formulary exception may exist. A benefit exclusion can be broader and may block the drug class, benefit, or use.

Is an appeal worth it when the letter says benefit exclusion?

It can be worth one focused round to test whether the plan used the right exclusion and whether an override or separate covered use exists. It is lower-yield when you are only resending the same records against clear plan language.

Can HR add GLP-1 coverage to my plan?

HR usually cannot reverse an individual medical review. On a self-funded plan, the employer or plan sponsor usually controls benefit design and may change it through an amendment or future renewal. The benefits team can identify the owner, record demand, and tell you whether any exception exists.

Why does the drug show as covered on my PBM's site when my plan says no?

A public drug list can cover many plan designs. Your member plan may exclude a benefit that the general list does not show. Ask for the formulary and plan terms tied to your exact member ID and plan year.

Will switching doctors or telehealth companies fix a plan exclusion?

No. A new prescriber may improve a weak PA submission. A prescriber cannot add a benefit your plan does not include.

Can I use another diagnosis to get coverage?

Only a real diagnosis in your medical record may be submitted. Ask your clinician whether you have another diagnosed condition with its own FDA-approved use and plan policy. Never ask anyone to submit a condition you do not have.

Does paying cash require prior authorization?

No. Prior authorization is an insurance-payment rule, so it does not apply when no insurance claim is submitted. You still need a valid prescription and a clinician who decides the treatment is appropriate.

Does the Medicare GLP-1 Bridge require prior authorization?

Yes. A pharmacy claim must first run through the Bridge routing, and the Bridge uses prior authorization. CMS says there is no appeal of a Bridge PA denial inside the Bridge process, but the prescriber may resubmit corrected or added information.

Does being on the drug already guarantee continued coverage?

No. The federal concurrent-care protection is limited to cutting short a previously approved course before its approved end. It does not automatically renew an expired PA or block a plan or formulary change.

What records should I keep?

Keep the denial notice, Explanation of Benefits, plan provision, current PA policy, everything the prescriber submitted, submission receipts, appeal copies, and a call log with names, dates, reference numbers, and promised follow-up dates.

How often should I recheck my coverage?

At every plan renewal, after any formulary notice, before a new prescription or renewal, and whenever the pharmacy price changes without a clear reason. Always ask for the policy effective date.

---

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

You already did the hard part: you found the gate that failed. Now match the path to your state, insurance situation, medication preference, and budget.

→ Find My GLP-1 Path

Free. About 60 seconds. FDA-approved and compounded paths are kept separate.

---

Related guides

• How to get insurance to cover a GLP-1
• GLP-1 providers that help with prior authorization
• Understand your GLP-1 formulary tier
• Legitimate GLP-1 treatment paths without prior authorization
• Medicare GLP-1 Bridge eligibility and prior authorization
• GLP-1 insurance appeal letter template

---

Sources — last rechecked August 24, 2026

• 45 CFR 147.136 — federal internal claims and appeals and external review rules, including denial-notice content, medical-judgment scope, plan-term limits, the worked exclusion example, deemed exhaustion, and external-review document deadlines.
• 29 CFR 2560.503-1 — the concurrent-care rule for reducing or ending a previously approved course of treatment before its approved end.
• HealthCare.gov: Internal Appeals and External Review — eligible denial types, filing windows, decision times, costs, authorized representatives, and the live October 2, 2026 extension.
• Social Security Act §1860D-2 and §1927 — the Part D treatment of agents when used for anorexia, weight loss, or weight gain and reconsideration/appeal of plan-applied exclusions.
• CMS: Medicare GLP-1 Bridge — program dates, covered products, $50 copay, eligibility, pharmacy routing, prior authorization, resubmission, and TrOOP treatment.
• 29 U.S.C. §1024, 29 U.S.C. §1132, and 29 CFR 2575.502c-1 — ERISA plan-document requests, the 30-day period, and the court's power to impose up to $110 per day.
• NAIC: Employee Retirement Income Security Act and U.S. Department of Labor: ERISA — self-funded versus insured plan regulation and plans outside ERISA.
• Massachusetts Board of Hearings — official decisions 2205321, 2304749, 2410692, 2505725, 2506857, 2510621, 2510925, 2511025, and 2514230.
• Official pharmacy code materials — Louisiana Medicaid denied-claim codes, New York Medicaid reject-code examples, New York Medicaid/NYRx code MR, and MaineCare code 75, 76, and 79 examples.
• Cigna Drug Policy A-Z Index and Cigna National Formulary Policy Index — current ordinary GLP-1 prior authorization policies and separately named GLP-1 Benefit Exclusion Override policies.
• FDA: Wegovy cardiovascular indication, FDA: Zepbound for obstructive sleep apnea, Wegovy at Drugs@FDA, and FDA: Foundayo approval — current approved uses named on this page.
• FDA: Compounding and FDA — Questions and Answers — compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
• Ro Body pricing, Ro's GLP-1 insurance checker, and Ro weight-loss program information — provider-stated checker scope, concierge support, products, and membership pricing.

Content is for informational purposes only and does not constitute medical advice, legal advice, or a promise of coverage. Consult your clinician and follow the appeal instructions in your own plan documents.

---